Page last updated: 2024-08-21

pyrazines and mitoxantrone

pyrazines has been researched along with mitoxantrone in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dreyling, M; Hiddemann, W; Lang, N; Pastore, A; Rieken, M; Weigert, O1
Buda, G; Galimberti, S; Orciuolo, E; Pelosini, M; Petrini, M1
Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ1
Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kathawala, RJ; Patel, A; Robey, RW; Shukla, S; Talele, TT; Wang, YJ; Zhang, H; Zhang, YK1
Batár, P; Bedekovics, J; Hevessy, Z; Illés, A; Kiss, A; Márton, A; Pinczés, L; Rejtő, L; Reményi, G; Selmeczi, A; Szász, R; Telek, B; Udvardy, M; Ujfalusi, A; Ujj, Z1

Reviews

1 review(s) available for pyrazines and mitoxantrone

ArticleYear
[Current treatment of acute myeloid leukaemia in adults].
    Orvosi hetilap, 2012, Feb-19, Volume: 153, Issue:7

    Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin

2012

Other Studies

4 other study(ies) available for pyrazines and mitoxantrone

ArticleYear
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
    Leukemia, 2007, Volume: 21, Issue:3

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisone; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Radioimmunotherapy; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Vidarabine; Vincristine; Yttrium Radioisotopes

2007
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Annals of hematology, 2011, Volume: 90, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine

2011
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
    The international journal of biochemistry & cell biology, 2014, Volume: 51

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Interactions; Drug Resistance, Multiple; HEK293 Cells; Humans; Imidazoles; Lung Neoplasms; Mitoxantrone; Models, Molecular; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Pyrazines

2014
[Treatment of acute myeloid leukemia -- a single center experience (2007-2013)].
    Orvosi hetilap, 2014, Apr-27, Volume: 155, Issue:17

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Hungary; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Palliative Care; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Survival Rate; Transplantation, Homologous; Treatment Outcome; Vidarabine

2014